Breaking News, Collaborations & Alliances

HaemaLogiX, Peter MacCallum Cancer Centre Partner on Myeloma CAR-T Trial

Peter Mac will develop technology, method of manufacturing, and conduct the Phase I trial of KMA.CAR-T in kappa-type multiple myeloma.

HaemaLogiX Ltd., a clinical stage biotech company, has entered into a co-development agreement with the Peter MacCallum Cancer Centre to conduct the first in human Phase I trial of HaemaLogiX’s CAR-T immunotherapy, KMA.CAR-T, for kappa-type multiple myeloma. HaemaLogiX brings its KappaMab technology to the collaboration and Peter Mac will develop the technology, method of manufacturing, and conduct the trial. KMA.CAR-T is a novel immunotherapy that targets a receptor called Kappa Mye...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters